

National Venture Capital Association (NVCA)

NVCA empowers the next generation of American companies that will fuel the economy of tomorrow.

As the voice of the U.S. venture capital and startup community, NVCA advocates for public policy that supports the American entrepreneurial ecosystem and arms the venture community for success, serving as the leading resource for venture capital data, practical education, peerled initiatives, and networking.





2. Bigger Funds, Investments, & Exits






3. Fewer Funds, Investments, & Exits


No. of U.S. VC Funds Closed



No. of U.S. VC Investments




No. of U.S. VC-backed Exits









5. Unicorns & Mega Deals Make Big Mark











6. New Players: Types of Investors + New VC Funds

% of All U.S. VC Deals (#) with Investor Participation









7. Record Year for Life Sciences

U.S. VC Life Science Investment Activity



U.S. VC Life Science Investment % of Total VC






Data as of 12/31/2018

8. VC Still Geographically Concentrated but Bright Spots in Emerging Ecosystems


VC Investment in CA+MA+NY as % of Total U.S.




Capital Invested (\$M)						
	2017	2018	YoY % Change			
Vermont	\$14	\$37	165%			
North Carolina	\$998	\$2,621	163%			
Ohio	\$410	\$1,026	150%			
Maryland						




What's Happening in Texas



2018 VC \$ Invested in TX was 2nd Highest in Decade; 6-year Low for Deal Count







Foreign investment scrutiny has significantly impacted the VC and startup ecosystem in recent months:

Foreign Investment Risk Review Modernization Act (FIRRMA) became law in August Who should care about FIRRMA?




MA?

Tax Policy

NVCA advocates for tax policy that encourages new company

formation





Drug Pricing: politics could motivate activity

Our role in this debate is educating policymakers on the crucial role venture capitalists play in new drug discovery


Political attacks on big drug companies could harm high-growth startups

Our July 2018 comments shared data on our industry's impact on medical innovation and stressed sensitivity toward how drug pricing reforms might influence early-stage investment in medicine





Blockchain Technology



VCs make some of the most critical technology investment decisions in the U.S. economy

Regulatory certainty for fully functional blockchain networks is critical to determining the full promise of the technology



Immigration: What is the fate of IER?

International Entrepreneur Rule (IER) is in place due to NVCA lawsuit, but DHS issued new rule to end IER

In May 2018, NVCA submitted comments and led coalition. To repeal IER, the administration needs to process vast amount of comments

Current state of Dept. Homeland Security has two possibilities Working on repeal order *or*

Their repeated attempts to repeal has chilled applications enough to effectively kill the program, but they are keeping IER on the books has benefit

H-1B rule



Volcker Rule Reform

NVCA submitted proposal to regulators in October

Allow bank investment into venture capital funds

Two regulatory paths to achieve proposal

Exempt VC

Regulatory parity













VC Definition Modernization (RIA)





Techlash (and implications for startups)

Big Tech is **on its heels** in DC as tech backlash has become bipartisan headache

Emboldened by the administration, Republicans no longer giving tech the benefit of doubt they give to private enterprise

Not to be outdone by the administration, Democrats stepping up historical criticism of data use



Questions? Contact NVCA